Sheffield cancer consultant named President of European group for rare pregnancy tumours
7 July 2025
A consultant medical oncologist from Sheffield Teaching Hospitals NHS Foundation Trust has become the new President of the European Organisation for Treatment of Trophoblastic Diseases (EOTTD).
Professor Matt Winter, Consultant Medical Oncologist at Weston Park Cancer Centre, was welcomed as the new President at the EOTTD Annual meeting in Madrid, Spain on 24 May.
He will reside in the role for a two-year term.
Matt, who joined Weston Park Cancer Centre in 2011 as a consultant, has dedicated his career to treating patients with breast cancer and gestational trophoblastic disease.
Gestational trophoblastic diseases are a rare group of conditions where tumours grow from the placental tissue formed during pregnancy.
In 2022 he became Director of the Sheffield Gestational Trophoblastic Centre, an internationally leading service based at Weston Park Cancer Centre and one of only two specialist national centres commissioned by NHS England to treat women with these rare tumours. The other centre is based at Charing Cross Hospital, in London.
Prior to the opening of national centres in 1973, nearly all patients died from the condition. However, over the past 50 years, the establishment of specialist centres has transformed outcomes for women diagnosed with the condition, with the disease now being up to 95 percent curable. The Sheffield centre treats patients from across the North of England..
As President of the EOTTD, Matt will play a leading role in helping to deliver the organisation’s aims of optimising diagnosis, treatment, follow-up and research in gestational trophoblastic disease by bringing together knowledge of clinicians, specialist nurses and researchers working in the field gestational trophoblastic disease throughout Europe.
Speaking of his appointment, Professor Matt Winter, Consultant Medical Oncologist at Weston Park Cancer Centre and Honorary Professor of Medical Oncology at the University of Sheffield, said:
“This is an extremely proud moment and one of the greatest honours of my career. In the UK, we are so fortunate to have a national Gestational Trophoblastic Disease service for screening and treatment at Weston Park Hospital in Sheffield and Charing Cross Hospital, London. Most other European countries do not have this and in such a rare disease, centralisation of care is essential to achieve the best outcomes for patients.
“As President of the EOTTD my goal is to help improve the care of patients with gestational trophoblastic disease locally, nationally and throughout Europe by raising awareness, and through collaborative teaching and research and help establish new gestational trophoblastic disease centres in countries that do not have them.”
Read more:
- Women share their stories to mark 50 years of the Sheffield Gestational Trophoblastic Disease Centre
- Sheffield Cancer Centre marks 50 years of world-leading care for rare cancer of the womb
- Young mum with rare tumour affecting one in 50,000 pregnancies praises Weston Park Cancer Centre on 50th anniversary
